Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population

Ähnliche Einträge

• Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
  von: Kevin Cowart, et al.
  Veröffentlicht: (2025)
• Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
  von: Scott A. Coon, et al.
  Veröffentlicht: (2025)
• Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data
  von: Gian Paolo Fadini, et al.
  Veröffentlicht: (2025)
• Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study
  von: Silvana Costa, et al.
  Veröffentlicht: (2025)
• Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
  von: Xi Tan, et al.
  Veröffentlicht: (2026)